Want to see NVNO full AI Analyst Report?
NVNO Stock Chart & Stats
$10.39
$0.28(2.69%)
At close: 4:00 PM EDT
$10.39
$0.28(2.69%)
Day’s Range― - ―
52-Week Range$8.67 - $49.35
Previous Close$10.77
Volume2.86K
Average Volume (3M)589.93K
Market Cap
$8.06M
Enterprise Value-$13.79
Total Cash (Recent Filing)$21.49M
Total Debt (Recent Filing)$505.00K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 05, 2026EPS Estimate
-3.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-520.08
Shares Outstanding682,722
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.00Price Target Upside188.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits financial risk and preserves flexibility while the company funds clinical development. Unlike a heavily debt-funded model, NVNO has fewer fixed financing obligations that could constrain investment in commercialization.
Pivotal Trial ProgressApproval to advance the pivotal TAVVE study moves enVVe toward clinical validation and potential commercialization. Successful execution could establish a non-surgical treatment option for severe venous disease and create a foundation for future regulatory and reimbursement efforts.
Health Economic SupportIndependent peer-reviewed evidence that venous valve replacement may improve outcomes while reducing costs strengthens the product's reimbursement case. Demonstrated economic value could support adoption by providers and payers if pivotal trial results confirm clinical benefits.
Bears Say
Pre-Revenue LossesNVNO has not yet generated commercial revenue and remains structurally dependent on development success before establishing a scalable business. Persistent operating losses indicate that profitability is distant and will depend on regulatory approval, launch execution, and market adoption.
Ongoing Cash BurnSustained negative operating and free cash flow means NVNO consumes capital to fund operations and clinical programs. The company will likely require continued access to financing until commercialization, creating funding dependence and potential execution risk if capital becomes less available.
Equity Dilution RiskThe sharp contraction in the equity base reflects the cumulative impact of ongoing losses and signals reduced balance-sheet support for future development. If cash burn persists, additional financing could dilute existing shareholders before the company reaches meaningful revenue.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $49.35 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $8.06M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Nov 05, 2026 which is in 77 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on Jul 31, 2026. The company reported -$5.37 earnings per share for the quarter, missing the consensus estimate of -$4.69 by -$0.68.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Undervalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate is -3.27.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 682,722 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -$5.37 in its last earnings report, missing expectations of -$4.69. Following the earnings report the stock price went down -0.245%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
NVNO Stock 12 Month Forecast
Average Price Target
$30.00
▲(188.74% Upside)
Technical Analysis
Ownership Overview
9.26% Insiders
1.87% Mutual Funds
10.54% Other Institutional Investors
77.41% Public Companies and
Individual Investors